Goldman Sachs
ANAB icon

Goldman Sachs’s AnaptysBio ANAB Stock Holding History

Goldman Sachs’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.5M Sell
332,743
-66,171
-17% -$3.56M ﹤0.01% 2511
2025
Q4 		$19.3M Buy
398,914
+69,094
+21% +$2.69M ﹤0.01% 2409
2025
Q3 		$10.1M Buy
329,820
+49,985
+18% +$1.15M ﹤0.01% 2956
2025
Q2 		$6.21M Sell
279,835
-742
-0.3% -$15.5K ﹤0.01% 3204
2025
Q1 		$5.22M Sell
280,577
-138,529
-33% -$2.31M ﹤0.01% 3309
2024
Q4 		$5.55M Buy
419,106
+68,742
+20% +$1.67M ﹤0.01% 3348
2024
Q3 		$11.7M Buy
350,364
+155,825
+80% +$5.32M ﹤0.01% 2558
2024
Q2 		$4.88M Buy
194,539
+44,108
+29% +$1.03M ﹤0.01% 3173
2024
Q1 		$3.39M Buy
150,431
+10,930
+8% +$259K ﹤0.01% 3437
2023
Q4 		$2.99M Sell
139,501
-38,900
-22% -$671K ﹤0.01% 3599
2023
Q3 		$3.2M Buy
178,401
+46,365
+35% +$885K ﹤0.01% 3377
2023
Q2 		$2.69M Sell
132,036
-53,564
-29% -$1.09M ﹤0.01% 3644
2023
Q1 		$4.04M Buy
185,600
+78,025
+73% +$1.9M ﹤0.01% 3247
2022
Q4 		$3.33M Buy
107,575
+11,487
+12% +$324K ﹤0.01% 3525
2022
Q3 		$2.45M Sell
96,088
-16,771
-15% -$393K ﹤0.01% 3808
2022
Q2 		$2.29M Sell
112,859
-116,974
-51% -$2.59M ﹤0.01% 3930
2022
Q1 		$5.69M Sell
229,833
-87,404
-28% -$2.65M ﹤0.01% 3233
2021
Q4 		$11M Sell
317,237
-30,385
-9% -$964K ﹤0.01% 2677
2021
Q3 		$9.43M Buy
347,622
+32,863
+10% +$834K ﹤0.01% 2786
2021
Q2 		$8.16M Sell
314,759
-112,293
-26% -$2.69M ﹤0.01% 2885
2021
Q1 		$9.2M Buy
427,052
+83,241
+24% +$2.1M ﹤0.01% 2636
2020
Q4 		$7.39M Buy
343,811
+80,120
+30% +$1.95M ﹤0.01% 2689
2020
Q3 		$3.89M Sell
263,691
-80,475
-23% -$1.45M ﹤0.01% 3088
2020
Q2 		$7.69M Buy
344,166
+237,809
+224% +$4.35M ﹤0.01% 2456
2020
Q1 		$1.5M Sell
106,357
-194,410
-65% -$2.95M ﹤0.01% 3492
2019
Q4 		$4.89M Buy
300,767
+149,647
+99% +$3.54M ﹤0.01% 2977
2019
Q3 		$5.29M Buy
151,120
+27,576
+22% +$1.31M ﹤0.01% 2820
2019
Q2 		$6.97M Buy
123,544
+8,298
+7% +$597K ﹤0.01% 2620
2019
Q1 		$8.42M Sell
115,246
-18,764
-14% -$1.3M ﹤0.01% 2559
2018
Q4 		$8.55M Sell
134,010
-36,569
-21% -$2.72M ﹤0.01% 2455
2018
Q3 		$17M Buy
170,579
+5,149
+3% +$427K ﹤0.01% 2040
2018
Q2 		$11.8M Buy
165,430
+124,718
+306% +$10.5M ﹤0.01% 2273
2018
Q1 		$4.24M Sell
40,712
-108,855
-73% -$12.3M ﹤0.01% 3031
2017
Q4 		$15.1M Buy
149,567
+42,004
+39% +$3.09M ﹤0.01% 2157
2017
Q3 		$3.76M Buy
107,563
+95,994
+830% +$2.59M ﹤0.01% 3423
2017
Q2 		$277K Buy
+11,569
New +$291K ﹤0.01% 5567

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs's ANAB Position: Q1 2026 in Review

Goldman Sachs reduced its AnaptysBio (ANAB) stake by 17% in Q1 2026, selling an estimated $3.56M and leaving 332,743 shares worth $18.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2511.

Goldman Sachs first reported a position in ANAB in Q2 2017 and has held it in 36 quarters since. The position peaked at $19.3M in Q4 2025. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Goldman Sachs held 332,743 shares of AnaptysBio worth $18.5M as of Q1 2026.
  • Goldman Sachs sold 66,171 AnaptysBio shares in Q1 2026, an estimated $3.56M.
  • AnaptysBio made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2511 holding.
  • Goldman Sachs first reported a position in AnaptysBio in Q2 2017 and has held it in 36 quarters since.
  • Goldman Sachs's AnaptysBio position peaked at $19.3M in Q4 2025.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.